Please use this identifier to cite or link to this item:
Title: Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus
Authors: Tim R. Cressey
Linda Harrison
Jullapong Achalapong
Prateep Kanjanavikai
Orada Patamasingh Na Ayudhaya
Prateung Liampongsabuddhi
Thitiporn Siriwachirachai
Chaiwat Putiyanun
Pornnapa Suriyachai
Camlin Tierney
Nicolas Salvadori
Dujrudee Chinwong
Luc Decker
Yardpiroon Tawon
Trudy V. Murphy
Nicole Ngo-Giang-Huong
George K. Siberry
Gonzague Jourdain
Keywords: Medicine
Pharmacology, Toxicology and Pharmaceutics
Issue Date: 1-Dec-2018
Abstract: Copyright © 2018 American Society for Microbiology. We assessed tenofovir exposure during pregnancy and postpartum in hepatitis B virus (HBV)-infected HIV-uninfected women receiving tenofovir disoproxil fumarate (TDF) to prevent mother-to-child transmission of HBV. Data from 154 women who received TDF within a randomized controlled trial were included. Individual plasma tenofovir exposures (area under the concentration-time curve from 0 to 24 h [AUC0-24]) were estimated using a population pharmacokinetic approach. The estimated geometric mean tenofovir AUC0-24 was 20% (95% confidence interval [95% CI], 19 to 21%) lower during pregnancy than during postpartum; this modest reduction in the absence of HBV transmission suggests that no dose adjustment is needed.
ISSN: 10986596
Appears in Collections:CMUL: Journal Articles

Files in This Item:
There are no files associated with this item.

Items in CMUIR are protected by copyright, with all rights reserved, unless otherwise indicated.